Embecta Corp. Leadership

Ms. Anderson served as the Executive Vice President and Chief Financial Officer for The Campbell's Company (NASDAQ: CPB) until October 2025. Prior to joining Campbell's in 2023, Ms. Anderson served as Executive Vice President and Chief Financial Officer for Integra LifeSciences Holdings Corporation (NASDAQ: IART). Prior to joining Integra in June 2019, she was Vice President and Controller of Dover Corporation. Ms. Anderson brings to the Board her financial expertise, life sciences experience and experience working with large, diversified global manufacturing companies, as well as her extensive experience in executive leadership, strategy and innovation, risk and crisis management, consumer/retail, ESG and experience with institutional investors.

Mr. Hombach served as Executive Vice President, Chief Financial Officer and Chief Operations Officer of Baxalta Incorporated until 2016, a biopharmaceutical company spun out from Baxter International, Inc. (NYSE: BAX). He served as Corporate Vice President and Chief Financial Officer of Baxter from July 2010 until the spinoff in 2015. Mr. Hombach is currently a member of the Board of Directors of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and Henry Schein, Inc. (NASDAQ: HSIC). Mr. Hombach brings to the Board his financial expertise and public company governance experience, as well as his experience in the medical device industry and with medical device technology, experience with strategic and transactional transitions, global business, operations and manufacturing, cybersecurity and information systems, risk and crisis management, experience with institutional investors, and payer and medical reimbursement experience.

Mr. Kurdikar is the President and Chief Executive Officer of Embecta. Previously, Mr. Kurdikar was the Worldwide President of Diabetes Care at BD. Prior to that role, Mr. Kurdikar was the President and CEO of Cardiac Science Corporation, a global leader in the manufacturing and marketing of automated external defibrillators for public access markets. Mr. Kurdikar is currently a member of the Board of Directors of Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), AdvaMed (Advanced Medical Technology Association) and LMG Holdings (a portfolio company of The Riverside Company).

Dr. Morris is a medical device C-Suite Executive and a public/private company independent board member. He most recently led Neuspera Medical, Inc., as Chairman and CEO. Prior to joining Neuspera, Dr. Morris was the Senior Vice President of Research & Development and Emerging Therapies at Cyberonics, Inc. (now LivaNova, PLC). Dr. Morris is a member of the Board of Directors of Myomo, Inc. (NYSE: MYO) and of Nordson Corporation (NASDAQ: NDSN).

Dr. Pomeroy has served since 2013 as President of the Albert and Mary Lasker Foundation, a private foundation that seeks to improve health by accelerating support for medical research through recognition of research excellence, public education and advocacy. Prior thereto, she served as Dean and Vice Chancellor of the University of California, Davis School of Medicine. She is an elected member of the National Academy of Medicine. Dr. Pomeroy is a member of the Board of Directors of Haemonetics Corporation (NYSE: HAE).

Ms. Prange was most recently Executive Vice President and Chief Executive Officer for the Global Animal Health, Medical and Dental Surgical Group at Henry Schein, Inc. and a member of its Executive Committee from 2016 to 2018. In this role, she led a business that generated over $6 billion of revenue across three different business units, growing the business to above-market levels in all business segments. Prior to her role at Henry Schein, she was Senior Vice President of Boston Scientific and President of its Urology and Pelvic Health business and served as General Manager of the Micrus Endovascular and Codman Neurovascular business at Johnson & Johnson Company. Ms. Prange currently serves on the board of AtriCure, Inc. (NASDAQ: ATRC) and WS Audiology A/S.

Mr. Reidy retired from BD in 2022, where he served as Executive Vice President, Chief Administrative Officer. He served as Executive Vice President, Chief Financial Officer of BD from July 2013 to September 2021. Prior to BD, Mr. Reidy served at ADP Corporation as Corporate Vice President and Chief Financial Officer for six years. Mr. Reidy currently serves on the Board of Directors of Encompass Health Corporation (NYSE: EHC) and is the Chair of its Audit Committee and a member of its Compliance/Quality of Care Committee.

LTG (Ret.) David F. Melcher served as Chairman of the Board of Embecta and is independent under the Nasdaq rules and the Company's director independence guidelines. As previously announced, LTG (Ret.) Melcher will not be standing for re-election at the 2026 Annual Meeting and will retire from the Board at the end of his current term expiring at the 2026 Annual Meeting.

Mr. David J. Albritton served as a director of Embecta and the Board determined that he was independent during the time he served on the Board. Mr. Albritton retired from the Board effective November 17, 2025.

Jacob (Jake) Elguicze serves as Senior Vice President and Chief Financial Officer, prior to which he served as Senior Vice President, Finance of Diabetes Care at BD until the Separation. Previously, Jake was the Treasurer and Vice President of Investor Relations of Teleflex Incorporated (NYSE: TFX), a global provider of medical technologies designed to improve the health and quality of people's lives. Prior to that role, Jake worked at Motorola, Inc. in a variety of corporate finance roles of increasing responsibility, including most recently the Director of Finance for one of Motorola's strategic business units.

Shaun Curtis serves as Senior Vice President, Global Manufacturing, Supply Chain and Quality, prior to which he served as the Worldwide Vice President of Operations for Diabetes Care at BD, from 2018 until the Separation. Previously, Shaun was the Manufacturing Director at BD Plymouth, UK (part of the Integrated Diagnostic Solutions Business) since 2012. Prior to joining BD, Shaun was the Engineering Manager at Cooper Standard Automotive, Plymouth, UK.

Jeff Mann serves as Senior Vice President, General Counsel and Product Development, prior to which he served as the Senior Vice President, General Counsel and Head of Corporate Development of Diabetes Care at BD until the Separation. Previously, Jeff served as General Counsel and Corporate Secretary of Cantel Medical Corp. Prior to Cantel, Jeff spent 14 years with Boston Scientific Corporation in roles including M&A, venture capital investments, SEC and corporate governance, patent strategy, litigation, and business unit support for the Med Surg group.

Jean Casner serves as Senior Vice President and Chief Human Resources Officer, and has over 30 years of global human resources strategy, design and operations experience across a range of industries. Most recently, she served as Senior Vice President and Chief Human Resources Officer for Renalytix, PLC, an emerging in-vitro diagnostic medical device company. Prior to Renalytix, Jean served as Senior Vice President & Chief Human Resources Officer of Cantel Medical Corp., a global medical products company focused on infection prevention products.

Ginny Blocki serves as Senior Vice President, Strategy of Embecta, having previously served in various roles at Embecta and as Senior Vice President, Product Management and Global Marketing of Diabetes Care at BD until the Separation. Earlier she led U.S. medication delivery marketing at Baxter International and held leadership roles at Assertio Therapeutics, Abbott Laboratories and Baxalta.

Tom Blount serves as Senior Vice President and President, North America of Embecta. He joined BD in 2016 and served as Vice President and General Manager, U.S. Diabetes Care from May 2020 until the Separation, after 16 years at Sanofi and five years of active duty in the U.S. Army.

Slobodan Radumilo serves as Senior Vice President and President, International of Embecta, prior to which he was Vice President and General Manager of Diabetes Care for BD in the EMEA region from 2016 until the Separation. He earlier held roles of increasing responsibility at Medtronic from 1997 to 2016.

Anthony Roth serves as Vice President, Chief Accounting Officer and Corporate Controller of Embecta. Before joining Embecta he was Senior Vice President, Chief Accounting Officer for Ascential plc's digital commerce business, and earlier held Chief Accounting Officer and Corporate Controller roles at Summit Health and Phibro Animal Health Corporation.

Brian Capone became Vice President, Chief Accounting Officer and Corporate Controller of Embecta as of the Effective Time of the spin-off from Becton, Dickinson and Company on April 1, 2022. On August 7, 2024, he notified the Company of his resignation as Chief Accounting Officer and principal accounting officer, effective August 12, 2024, in order to pursue another opportunity. His departure was not due to any disagreement with the Company on any matter relating to its financial statements, internal control over financial reporting, operations, policies or practices.

Ajay Kumar became Senior Vice President and Chief Human Resources Officer of Embecta as of the Effective Time of the spin-off from Becton, Dickinson and Company on April 1, 2022. On June 29, 2023, Mr. Kumar and the Company mutually agreed to his resignation from the role of Chief Human Resources Officer, effective July 16, 2023.